SPAS(SH:603168) Zheng Quan Zhi Xing·2025-09-03 16:08Summary of Key Points Core Viewpoint - The major shareholder of Zhejiang Shapuaisi Pharmaceutical Co., Ltd., Mr. Chen Dekang, plans to reduce his shareholding due to personal financial needs, with specific limits on the number of shares to be sold and the methods of sale [1][2]. Group 1: Shareholder Information - Mr. Chen Dekang holds 43,871,004 shares, representing 11.67% of the total shares [2]. - The shares held by Mr. Chen include 33,494,281 shares acquired before the IPO and 10,376,723 shares obtained through other means [2]. Group 2: Reduction Plan Details - The reduction plan allows for a maximum of 7,518,500 shares to be sold, which is up to 2.00% of the total share capital [2]. - The plan specifies that up to 3,759,250 shares may be sold through centralized bidding and another 3,759,250 shares through block trading [1][2]. - The reduction period is set from September 25, 2025, to December 24, 2025 [1][2]. Group 3: Compliance and Commitments - Mr. Chen has made prior commitments regarding shareholding, including a lock-up period and conditions under which he may reduce his holdings [3][4]. - The company and Mr. Chen will adhere to relevant laws and regulations during the reduction process, ensuring timely disclosure of information [6].